Core Viewpoint - Amaroq Ltd. is proceeding with the voluntary delisting of its common shares from the TSX Venture Exchange, effective March 19, 2026, while continuing to trade on other exchanges [2][3]. Company Information - Amaroq Ltd. is an independent mine development corporation focused on mineral exploration in Greenland, particularly gold and strategic metals [9]. - The company holds a 100% interest in the Nalunaq Gold mine and has a portfolio that includes advanced exploration projects for copper, nickel, rare earths, and other minerals in Southern Greenland [9]. Shareholder Information - Canadian shareholders wishing to trade shares on AIM or Nasdaq Iceland must ensure their shares are eligible for transfer and settlement through CREST, the UK-based share transfer system [4]. - Shareholders can initiate the transfer process through their brokers or by contacting Computershare Trust Company of Canada [5][6]. - The company will maintain CDS eligibility for its shares until April 30, 2026, to facilitate this transition for Canadian shareholders [6]. Ongoing Obligations - Despite the delisting from the TSXV, Amaroq Ltd. will continue to meet ongoing disclosure and other obligations as a reporting issuer under Canadian securities legislation [7].

Core Points - LAVA Therapeutics announced that approximately 87% of its outstanding common shares were validly tendered in the tender offer by XOMA Royalty Corporation, satisfying the minimum tender condition [1] - The subsequent offering period for LAVA shareholders to tender their shares will expire on November 20, 2025, and shares tendered during this period cannot be withdrawn [2] - LAVA intends to voluntarily delist its common shares from Nasdaq, contingent upon the completion of the acquisition by XOMA Royalty [3] Company Overview - LAVA Therapeutics is a biopharmaceutical company focused on developing bispecific gamma delta T cell engagers using its proprietary Gammabody® platform, with partnerships with Johnson & Johnson and Pfizer for specific cancer treatments [4]